June 29, 2020 – After being scrutinized for years regarding drug pricing issues, the biopharma industry is enjoying a boost in public opinion during the COVID-19 crisis. However, that boost may slowly be fading as lawmakers and the public continue to be skeptical of the industry, as evidenced by two bills introduced in the House […]
Read more
May 11, 2020 – A bill that proposed a Maryland tax on “digital advertising services” that was approved by the state legislature in March was vetoed on May 7 by Maryland Gov. Larry Hogan (R), stopping, at least for now, the nation’s first tax on digital advertising. In his veto letter, Hogan stated that the […]
Read more April 6, 2020 – The Coalition for Healthcare Communication last week endorsed an urgent request to Maryland Governor Larry Hogan (R) to veto HB 732, which would put in place the nation’s first tax on digital advertising. The request, sent March 31 by national media and advertising trade associations and members of The Advertising Coalition, […]
Read more March 30, 2020 – In addition to providing millions of Americans and many industries with financial support during the coronavirus outbreak, the emergency relief bill passed by Congress and signed into law by President Donald Trump on Friday accrues additional funding for the Food and Drug Administration’s coronavirus efforts and makes important changes to how […]
Read more Nov. 11, 2019 – As Congress works to agree on legislation that would rein in drug prices, a bill co-sponsored by Sen. Charles Grassley (R-Iowa) and Sen. Dick Durbin (D-Ill.) – which would require that list prices be included in direct-to-consumer (DTC) television advertisements – may be close to a vote. Grassley and Durbin hoped […]
Read more Sept. 20, 2019 – Although the House proposal unveiled by House Speaker Nancy Pelosi (D-Calif.) to combat high drug prices would cap Medicare drug prices based on the average price in six developed countries, require that the federal government and drug companies negotiate prices for up to 250 of the most expensive prescription drugs, mandate […]
Read more
June 11, 2019 – Although pharmaceutical advertisers have been able to stop legislation to eliminate or reduce the deductibility of drug advertising as a business expense in the past, the times, politics and a pressing need for revenue have changed the equation, according to Jim Davidson, chair of The Advertising Coalition. “It is very much […]
Read more March 25, 2019 – Several moves that could change the way prescription drug marketing and communications are conducted are being made in Washington, with the House Ways and Means Committee about to begin markup on a tax measure that could include eliminating the deductibility of drug marketing costs, and the Office of Management and Budget […]
Read more Jan. 16, 2019 – Sens. Jeanne Shaheen (D-N.H.) and Elizabeth Warren (D-Mass.) have co-authored a bill that would “deny the deduction for advertising and promotional expenses for prescription drugs.” The bill, announced Jan. 11, is titled the “End Taxpayer Subsidies for Drug Ads Act.” “This bill raises significant First Amendment questions,” pointed out Jon Bigelow, […]
Read more
Sept. 27, 2018 – Although it was the Obama administration’s position that reprints and textbooks received by physicians were transfers of value that were fully reportable under the Sunshine Act Open Payments regulation, the Trump administration and Congress are taking another look at the matter, according to John Kamp, Washington Counsel, Coalition for Healthcare Communication. […]
Read more